Medical and Pharmacy Expenditures After Implementation of a Cyclooxygenase-2 Inhibitor Prior Authorization Program
| Autor: | Patrick P. Gleason, Sally Hrdy, Steven C. Hartwig, David Lassen, Clint Williams |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Risk medicine.medical_specialty Abdominal pain Adolescent Gastrointestinal Diseases Cost-Benefit Analysis Pharmacy Pharmacology Drug Prescriptions Cohort Studies Reimbursement Mechanisms Lactones medicine Humans Cyclooxygenase Inhibitors Pharmacology (medical) Prospective Studies Sulfones Prior authorization Medical prescription Child Adverse effect Utilization management Aged Cyclooxygenase 2 Inhibitors business.industry Infant Newborn Infant Membrane Proteins Health Care Costs Emergency department Middle Aged Drug Utilization Cyclooxygenase 2 Prostaglandin-Endoperoxide Synthases Child Preschool Emergency medicine Female Health Expenditures medicine.symptom business Cohort study |
| Zdroj: | Pharmacotherapy. 25:924-934 |
| ISSN: | 0277-0008 |
| Popis: | Study Objective. To evaluate the effects of a cyclooxygenase (COX)-2 inhibitor prior authorization (PA) program on direct medical and pharmacy costs. Design. Prospective, pre- and postimplementation cohort study with reference group. Setting. Large corporation in the Midwest. Patients. Of 26,375 continuously enrolled members, 737 used a COX-2 inhibitor in the 3 months before January 1, 2003, when the PA program was implemented. Measurement and Main Results. The PA program limits coverage for a COX-2 inhibitor to members with a documented risk for a nonselective nonsteroidal antiinflammatory drug (NSAID)–induced gastrointestinal adverse event. All pharmacy and medical claims and costs were analyzed payer's perspective for a 15-month period. Separate pharmacy cost comparisons and medical cost comparisons were made between the 3-month quarter before PA program implementation and each follow-up quarter after PA program implementation. In the 3 months after PA program implementation, 620 (84.1%) of 737 members had no claims for a COX-2 inhibitor, and during this period their pharmacy and medical costs initially declined 40.0% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text